Enliven Therapeutics (ELVN) PT Raised to $45 at BTIG, 'We increase our PoS for the ELVN-001 program and remove ELVN-002 from our model for HER2+ solid tumors'
Tweet Send to a Friend
BTIG analyst Justin Zelin raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $45.00 (from $42.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
